TEM Tempus AI
Clinical and genomic data for AI diagnostics
Fundamentals from public market data, refreshed daily (2026-10-24 02:59 UTC). Figures in reporting currency.
TEM · price with what management and the data said
Timeline: management commentary, data & earnings
8 events-
8
2026-07-30EarningsBeat / raise
Reported EPS -0.04 vs -0.15 expected (+73.6% surprise).
-
7
2026-05-05EarningsBeat / raise
Reported EPS -0.13 vs -0.2 expected (+35.4% surprise).
-
6
2026-02-24EarningsBeat / raise
Reported EPS -0.04 vs -0.05 expected (+22.1% surprise).
-
5
2025-11-04EarningsBeat / raise
Reported EPS -0.11 vs -0.18 expected (+37.3% surprise).
-
4
2025-08-08EarningsBeat / raise
Reported EPS -0.22 vs -0.25 expected (+13.0% surprise).
-
3
2025-05-06EarningsBeat / raise
Reported EPS -0.24 vs -0.27 expected (+10.2% surprise).
-
2
2025-02-24EarningsMiss / cut
Reported EPS -0.18 vs -0.15 expected (-17.5% surprise).
-
1
2024-11-04EarningsBeat / raise
Reported EPS -0.25 vs -0.31 expected (+19.5% surprise).
Latest headlines
Auto-updated daily- Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data2026-10-23
- Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions2026-10-23
- Should You Be Worried About Tempus AI Stock?2026-10-20
- Tempus AI Stock Is The Expanded Drug Collaboration Material To The Bull Case2026-10-17
- Tempus AI Expands Strategic Collaborations to Drive Future Growth2026-10-12
- Could You Have Seen The Run In Tempus AI Stock Coming?2026-10-09
Earnings history
EPS vs expectations| Date | Expected EPS | Reported EPS | Surprise |
|---|---|---|---|
| 2026-07-30 | -0.15 | -0.04 | +73.6% |
| 2026-05-05 | -0.2 | -0.13 | +35.4% |
| 2026-02-24 | -0.05 | -0.04 | +22.1% |
| 2025-11-04 | -0.18 | -0.11 | +37.3% |
| 2025-08-08 | -0.25 | -0.22 | +13.0% |
| 2025-05-06 | -0.27 | -0.24 | +10.2% |
| 2025-02-24 | -0.15 | -0.18 | −17.5% |
| 2024-11-04 | -0.31 | -0.25 | +19.5% |
| 2024-08-06 | -1.79 | -0.63 | +64.8% |
About Tempus AI
Website ↗Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findin…
Models now design molecules and antibodies, but clinical trials are still the gate. Value accrues to platforms with wet-lab data and pharma partnerships.
What would prove us wrong. Weakens if AI-designed candidates fail in the clinic at rates no better than traditional discovery.
Who else supplies this
| Stock | Role | Last | 1D | 1M | YTD | Trend |
|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | AI drug discovery with NVIDIA-backed compute | $3.77 | +1.89% | +0.8% | −7.8% | |
| SDGR Schrödinger | Physics-plus-AI molecular design software | $24.60 | +3.36% | −14.7% | +37.6% | |
| ABSI Absci | Generative-AI antibody design | $9.55 | +4.03% | −1.9% | +173.6% | |
| ABCL AbCellera Biologics | AI-driven antibody discovery | $12.15 | +2.81% | −4.3% | +255.3% |
Not investment advice. Prices delayed and in local currency. Quotes in "double quotes" are verbatim as reported by the linked source; other commentary is our paraphrase. Earnings dates are estimates.